SABINA: global programme to evaluate prescriptions and clinical outcomes related to short-acting β₂-agonist use in asthma

Eur Respir J. 2020 Feb 12;55(2):1901858. doi: 10.1183/13993003.01858-2019. Print 2020 Feb.

Authors

Claudia S Cabrera^{1

2

3}, Cassandra Nan^{4

3}, Niklas Lindarck⁵, Maarten J H I Beekman⁶, Sofie Arnetorp¹, Ralf J P van der Valk⁷

Affiliations

¹ AstraZeneca, Gothenburg, Sweden.
² Dept of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden.
³ Co-first authors.
⁴ AstraZeneca, Gothenburg, Sweden [email protected].
⁵ AstraZeneca, Södertälje, Sweden.
⁶ AstraZeneca, The Hague, The Netherlands.
⁷ AstraZeneca, Cambridge, UK.

PMID: 31806716
DOI: 10.1183/13993003.01858-2019

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Administration, Inhalation
Adrenergic beta-2 Receptor Agonists / therapeutic use
Adrenergic beta-Agonists / therapeutic use
Asthma* / drug therapy
Humans
Prescriptions

Substances

Adrenergic beta-2 Receptor Agonists
Adrenergic beta-Agonists